CLINICAL RESEARCH: CORONARY ARTERY DISEASE
Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in HumansEvidence of a Free-Radical–Mediated Mechanism
George R. Thomas, PhD*,
Jonathan M. DiFabio, MSc*,
Tommaso Gori, MD, PhD and
John D. Parker, MD, FACC*,*
* Division of Cardiology, Department of Medicine, University Health Network and Mount Sinai Hospitals and the Department of Pharmacology, University of Toronto, Toronto, Canada
Department of Internal, Cardiovascular and Geriatric Medicine, University of Siena, Siena, Italy. Supported by a research donation from the Henry White Kinnear Foundation. Dr. Parker holds a Career Investigator Award from the Heart and Stroke Foundation of Ontario, Canada. Dr. Gori is the recipient of a grant from the Italian Ministry of Research
Manuscript received May 19, 2006;
revised manuscript received September 13, 2006,
accepted October 12, 2006.
* Reprint requests and correspondence: Dr. John D. Parker, Mount Sinai Hospital, 600 University Avenue, Room 1609, Toronto, Ontario, Canada, M5G 1X5. (Email: jdp{at}ca.inter.net).
Objectives: The aim of the study was to determine if isosorbide-5-mononitrate (IS-5-MN) 120 mg, taken once daily for 7 days, is associated with evidence of endothelial dysfunction and whether this effect is determined by increased free radical production.
Background: Tolerance to nitroglycerin is associated with increased free radical production and abnormal endothelial function. To date, no data is available concerning the effect of IS-5-MN, administered in clinically employed dosages, on endothelial function in humans.
Methods: A total of 19 healthy volunteers were randomized in a double-blind fashion to therapy with IS-5-MN (120 mg once daily) or placebo. After 7 days of treatment, forearm blood flow responses to acetylcholine (Ach; 7.5, 15, and 30 µg/min) and N-monomethyl-L-arginine (L-NMMA; 1, 2, and 4 µmol/min) were measured. In a separate study, after 7 days of therapy with IS-5-MN 120 mg once daily, the responses to Ach were assessed during intra-arterial coinfusion of vitamin C (24 mg/min) or saline.
Results: As compared with placebo, IS-5-MN caused significant blunting of the responses to both Ach (peak responses: placebo 127 ± 31%; IS-5-MN 52 ± 24%) and L-NMMA (peak responses: placebo 41 ± 5%; IS-5-MN 22 ± 8%). Vitamin C completely restored the forearm blood flow responses to Ach (peak responses: vitamin C 180 ± 33%; saline 107 ± 17%).
Conclusions: We document for the first time that IS-5-MN impairs endothelial function in humans in vivo. Suggesting a role of oxygen free radicals, nitrate-induced abnormalities in endothelium-dependent vasomotor responses were reversed by the antioxidant vitamin C.
|
Abbreviations and Acronyms
| | Ach = acetylcholine | | FBF = forearm blood flow | | GTN = nitroglycerin | | IS-5-MN = isosorbide-5-mononitrate | | L-NMMA = N-monomethyl-L-arginine | | PETN = pentaerithrityl tetranitrate | | ROS = reactive oxygen species |
|
Related Article
-
Do We Still Need Organic Nitrates?
- Thomas Münzel, Philip Wenzel, and Andreas Daiber
J. Am. Coll. Cardiol. 2007 49: 1296-1298.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Knorr, M. Hausding, S. Kroller-Schuhmacher, S. Steven, M. Oelze, T. Heeren, A. Scholz, T. Gori, P. Wenzel, E. Schulz, et al.
Nitroglycerin-Induced Endothelial Dysfunction and Tolerance Involve Adverse Phosphorylation and S-Glutathionylation of Endothelial Nitric Oxide Synthase: Beneficial Effects of Therapy With the AT1 Receptor Blocker Telmisartan
Arterioscler Thromb Vasc Biol,
October 1, 2011;
31(10):
2223 - 2231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schuhmacher, M. Oelze, F. Bollmann, H. Kleinert, C. Otto, T. Heeren, S. Steven, M. Hausding, M. Knorr, A. Pautz, et al.
Vascular Dysfunction in Experimental Diabetes Is Improved by Pentaerithrityl Tetranitrate but Not Isosorbide-5-Mononitrate Therapy
Diabetes,
October 1, 2011;
60(10):
2608 - 2616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Munzel, A. Daiber, and T. Gori
Nitrate Therapy: New Aspects Concerning Molecular Action and Tolerance
Circulation,
May 17, 2011;
123(19):
2132 - 2144.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Liuni, M. C. Luca, G. Di Stolfo, A. Uxa, J. A. Mariani, T. Gori, and J. D. Parker
Coadministration of Atorvastatin Prevents Nitroglycerin-Induced Endothelial Dysfunction and Nitrate Tolerance in Healthy Humans
J. Am. Coll. Cardiol.,
January 4, 2011;
57(1):
93 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schuhmacher, P. Wenzel, E. Schulz, M. Oelze, C. Mang, J. Kamuf, T. Gori, T. Jansen, M. Knorr, S. Karbach, et al.
Pentaerythritol Tetranitrate Improves Angiotensin II-Induced Vascular Dysfunction via Induction of Heme Oxygenase-1
Hypertension,
April 1, 2010;
55(4):
897 - 904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gori, S. Dragoni, G. Di Stolfo, S. Sicuro, A. Liuni, M. C. Luca, G. Thomas, M. Oelze, A. Daiber, and J. D. Parker
Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study
Am J Physiol Heart Circ Physiol,
February 1, 2010;
298(2):
H340 - H345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Wenzel, E. Schulz, T. Gori, M. A. Ostad, F. Mathner, S. Schildknecht, S. Gobel, M. Oelze, D. Stalleicken, A. Warnholtz, et al.
Monitoring White Blood Cell Mitochondrial Aldehyde Dehydrogenase Activity: Implications for Nitrate Therapy in Humans
J. Pharmacol. Exp. Ther.,
July 1, 2009;
330(1):
63 - 71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gori and J. D. Parker
Nitrate-Induced Toxicity and Preconditioning: A Rationale for Reconsidering the Use of These Drugs
J. Am. Coll. Cardiol.,
July 22, 2008;
52(4):
251 - 254.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Moens, C. J. Vrints, M. J. Claeys, J.-P. Timmermans, H. C. Champion, and D. A. Kass
Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease
Am J Physiol Heart Circ Physiol,
May 1, 2008;
294(5):
H1971 - H1977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dragoni, T. Gori, M. Lisi, G. Di Stolfo, A. Pautz, H. Kleinert, and J. D. Parker
Pentaerythrityl Tetranitrate and Nitroglycerin, but not Isosorbide Mononitrate, Prevent Endothelial Dysfunction Induced by Ischemia and Reperfusion
Arterioscler Thromb Vasc Biol,
September 1, 2007;
27(9):
1955 - 1959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Munzel, P. Wenzel, and A. Daiber
Do We Still Need Organic Nitrates?
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1296 - 1298.
[Full Text]
[PDF]
|
|
|
|
